Erste Asset Management GmbH Has $16.62 Million Stake in Ginkgo Bioworks Holdings, Inc. $DNA

Erste Asset Management GmbH decreased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 9.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,000,000 shares of the company’s stock after selling 200,000 shares during the period. Erste Asset Management GmbH’s holdings in Ginkgo Bioworks were worth $16,620,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Ginkgo Bioworks by 4.2% in the third quarter. Vanguard Group Inc. now owns 2,480,504 shares of the company’s stock valued at $36,166,000 after buying an additional 99,379 shares during the period. Legal & General Group Plc lifted its holdings in Ginkgo Bioworks by 7.9% in the third quarter. Legal & General Group Plc now owns 1,608,923 shares of the company’s stock valued at $23,458,000 after buying an additional 118,402 shares during the period. Millennium Management LLC lifted its holdings in Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock valued at $8,137,000 after buying an additional 757,535 shares during the period. Geode Capital Management LLC increased its stake in Ginkgo Bioworks by 23.7% in the fourth quarter. Geode Capital Management LLC now owns 999,600 shares of the company’s stock valued at $8,309,000 after purchasing an additional 191,240 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Ginkgo Bioworks by 11.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 919,309 shares of the company’s stock valued at $7,639,000 after purchasing an additional 94,021 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.

Insider Buying and Selling at Ginkgo Bioworks

In other news, major shareholder Barry Canton sold 124,727 shares of the business’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $6.43, for a total transaction of $801,994.61. Following the completion of the sale, the insider directly owned 436,422 shares of the company’s stock, valued at $2,806,193.46. The trade was a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Reshma P. Shetty sold 124,727 shares of the business’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $6.43, for a total transaction of $801,994.61. Following the sale, the insider directly owned 436,422 shares of the company’s stock, valued at approximately $2,806,193.46. The trade was a 22.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 543,288 shares of company stock valued at $3,551,556. Insiders own 12.69% of the company’s stock.

Ginkgo Bioworks Price Performance

NYSE:DNA opened at $8.08 on Tuesday. The firm has a 50-day moving average of $7.96 and a 200-day moving average of $8.36. The company has a market cap of $527.46 million, a PE ratio of -1.51 and a beta of 1.79. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.37 and a one year high of $17.58.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on DNA shares. BTIG Research decreased their price target on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating for the company in a research note on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Monday, April 20th. Finally, Wall Street Zen downgraded shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $8.50.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.